AusperBio Achieves Significant Milestone with Patient Enrollment in AUSHINE Study for Chronic Hepatitis B AusperBio has successfully completed patient enrollment in its Phase III AUSHINE study, crucial for addressing chronic hepatitis B with AHB-137.

AusperBio Achieves Significant Milestone with Patient Enrollment in AUSHINE Study for Chronic Hepatitis B #USA #San_Francisco #AusperBio #AHB-137 #Chronic_Hepatitis_B

AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment AusperBio's recent findings on AHB-137's effectiveness in treating chronic hepatitis B offer new hope, achieving a 30% functional cure rate in patients.

AusperBio's AHB-137 Shows Promising Results for Hepatitis B Treatment #USA #San_Francisco #AusperBio #Hepatitis_B #AHA-137

AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025 At the AASLD 2025 Annual Meeting, AusperBio revealed promising 48-week Phase II data for AHB-137, enhancing treatment for chronic hepatitis B.

AusperBio Showcases 48-Week Phase II Data of AHB-137 for Chronic Hepatitis B at AASLD 2025 #Washington_D.C. #AusperBio #AHB-137 #Hepatitis_B

AusperBio Secures $63 Million to Transform Hepatitis B Treatments with Innovative Therapies AusperBio Therapeutics has successfully closed $63 million in Series B2 financing to advance innovative therapies aimed at curing chronic hepatitis B.

AusperBio Secures $63 Million to Transform Hepatitis B Treatments with Innovative Therapies #USA #San_Francisco #AusperBio #AHB-137 #Med-Oligo

AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B AusperBio Therapeutics has completed the enrollment for two pivotal Phase II trials of AHB-137, a potential treatment for chronic hepatitis B. The trials could redefine treatment strategies in the field.

AusperBio Achieves Milestone in AHB-137 Phase II Trials for Chronic Hepatitis B #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B

AusperBio Advances AHB-137 into Phase III Clinical Trials to Combat Chronic Hepatitis B in China AusperBio has received approval to initiate Phase III trials for AHB-137, a promising treatment for chronic hepatitis B, from China's drug evaluation body.

AusperBio Advances AHB-137 into Phase III Clinical Trials to Combat Chronic Hepatitis B in China #China #San_Francisco #AusperBio #AHB-137 #Chronic_Hepatitis_B

AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments AusperBio Therapeutics has successfully completed a $50 million Series B+ financing round to further develop innovative treatments for chronic hepatitis B.

AusperBio Secures $50 Million Funding to Enhance Chronic Hepatitis B Treatments #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B

AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025 AusperBio Therapeutics presents significant interim data for AHB-137 at the EASL Congress 2025, spotlighting its potential in hepatitis B treatment.

AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025 #United_States #San_Francisco #AusperBio #AHB-137 #EASL_Congress

AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B AusperBio has successfully closed a $73 million Series B financing round to enhance its efforts in developing a functional cure for chronic hepatitis B, showcasing investor confidence.

AusperBio Achieves $73 Million in Series B Funding to Combat Chronic Hepatitis B #USA #San_Francisco #AusperBio #AHB-137 #Hepatitis_B